What is HC Wainwright’s Forecast for PVLA FY2029 Earnings?

Palvella Therapeutics (NASDAQ:PVLA) – HC Wainwright issued their FY2029 earnings estimates for shares of Palvella Therapeutics in a report released on Friday, January 3rd. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.69) per share for the year. HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock.

Separately, Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $14.73 on Monday. The firm has a market cap of $19.44 million, a price-to-earnings ratio of -1.22 and a beta of 0.67. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $22.32.

Insider Activity at Palvella Therapeutics

In other news, Director George M. Jenkins purchased 4,000 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was bought at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the purchase, the director now directly owns 180,671 shares of the company’s stock, valued at $2,336,076.03. The trade was a 2.26 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.39% of the stock is owned by insiders.